2CUREX AB SEK-10 (2QE) - Total Liabilities
Based on the latest financial reports, 2CUREX AB SEK-10 (2QE) has total liabilities worth €4.55 Million EUR (≈ $5.32 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See 2QE working capital ratio to evaluate short-term liquidity relative to the company's equity base.
2CUREX AB SEK-10 - Total Liabilities Trend (2021–2024)
This chart illustrates how 2CUREX AB SEK-10's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 2CUREX AB SEK-10 balance sheet assets.
2CUREX AB SEK-10 Competitors by Total Liabilities
The table below lists competitors of 2CUREX AB SEK-10 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
QVC Group Inc
NASDAQ:QVCGB
|
USA | $10.23 Billion |
|
Aminex PLC
LSE:AEX
|
UK | GBX15.15 Million |
|
Foresight Ventures VCT plc
LSE:FVEN
|
UK | GBX2.04 Million |
|
TV Vision Limited
NSE:TVVISION
|
India | Rs1.96 Billion |
|
Applied DNA Sciences, Inc.
NASDAQ:BNBX
|
USA | $1.50 Million |
|
Volato Group Inc.
NYSE:SOAR
|
USA | $20.11 Million |
|
iPower Inc
NASDAQ:IPW
|
USA | $16.77 Million |
|
Gaming Realms plc
LSE:GMR
|
UK | GBX4.96 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down 2CUREX AB SEK-10's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 2QE equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 7.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.88 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 2CUREX AB SEK-10's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 2CUREX AB SEK-10 (2021–2024)
The table below shows the annual total liabilities of 2CUREX AB SEK-10 from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €3.03 Million ≈ $3.54 Million |
+467.73% |
| 2023-12-31 | €533.00K ≈ $623.13K |
-88.47% |
| 2022-12-31 | €4.62 Million ≈ $5.40 Million |
-4.01% |
| 2021-12-31 | €4.82 Million ≈ $5.63 Million |
-- |
About 2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.